000			01993na a2200229 4500
003			H12O
005			20191018062648.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH120
041			_aeng
100			_9388 _aLahuerta Palacios, Juan José _eHematología y Hemoterapia
245	0	0	_aGenomic analysis of high-risk smoldering multiple myeloma. _h[artículo]
260			_bHaematologica, _c2012
300			_a97(9):1439-43.
500			_aFormato Vancouver: López-Corral L, Mateos MV, Corchete LA, Sarasquete ME, de la Rubia J, de Arriba F, et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica. 2012 Sep;97(9):1439-43.
501			_aPMID: 22331267
504			_aContiene 24 referencias
520			_aSmoldering myeloma is an asymptomatic plasma cell dyscrasia with a heterogeneous propensity to progress to active myeloma. In order to investigate the biology of smoldering myeloma patients with high risk of progression, we analyzed the genomic characteristics by FISH, SNP-arrays and gene expression profile of a group of patients with high-risk smoldering myeloma included in a multicenter randomized trial. Chromosomal abnormalities detected by FISH and SNP-arrays at diagnosis were not associated to risk of progression to symptomatic myeloma. However, the overexpression of four SNORD genes (SNORD25, SNORD27, SNORD30 and SNORD31) was correlated with shorter time to progression (P<0.03). When plasma cells from high-risk smoldering patients who progressed to symptomatic myeloma were sequentially analyzed, newly acquired lesions together with an increase in the proportion of plasma cells carrying a given abnormality were observed. These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436247/ _yAcceso libre
942			_n0 _2ddc _cART
999			_c5053 _d5053